134 related articles for article (PubMed ID: 38193596)
1. A post hoc analysis of PROTECT VIII kids assessing long-term efficacy and safety of damoctocog alfa pegol in adolescents with severe haemophilia A.
Ahuja S; Biss T; Maas Enriquez M; Mancuso ME; Steele M; Kenet G
Eur J Haematol; 2024 May; 112(5):756-764. PubMed ID: 38193596
[TBL] [Abstract][Full Text] [Related]
2. PROTECT VIII kids extension study: Long-term safety and efficacy of BAY 94-9027 (damoctocog alfa pegol) in children with severe haemophilia A.
Mancuso ME; Biss T; Fischer K; Maas Enriquez M; Steele M; Wang M; Tseneklidou-Stoeter D; Ahuja S; Kenet G
Haemophilia; 2021 May; 27(3):434-444. PubMed ID: 33724632
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ⩾40 years with severe haemophilia A and comorbidities:
Reding MT; Pabinger I; Holme PA; Maas Enriquez M; Mancuso ME; Lalezari S; Miesbach W; Di Minno G; Klamroth R; Hermans C
Ther Adv Hematol; 2023; 14():20406207231166779. PubMed ID: 37113811
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of damoctocog alfa pegol prophylaxis in patients with severe haemophilia A: Results of an interventional, post-marketing study.
Holme PA; Poulsen LH; Tueckmantel C; Maas Enriquez M; Alvarez Román MT; De Cristofaro R
Haemophilia; 2024 Mar; 30(2):388-394. PubMed ID: 38229269
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Efficacy and Safety of Damoctocog Alfa Pegol Prophylaxis in Patients with Haemophilia A Aged 12-<18 Years at Enrolment into PROTECT VIII.
Reding MT; Simpson M; Ducore J; Holme PA; Maas Enriquez M; Mancuso ME
Acta Haematol; 2024 Apr; ():1-10. PubMed ID: 38599195
[TBL] [Abstract][Full Text] [Related]
6. Canadian clinical experience on switching from standard half-life recombinant factor VIII (rFVIII), octocog alfa, to extended half-life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada.
Matino D; Germini F; Chan AKC; Decker K; Iserman E; Chelle P; Edginton AN; Oladoyinbo O; Trinari E; Keepanasseril A; Iorio A
Haemophilia; 2024 Mar; 30(2):345-354. PubMed ID: 38379181
[TBL] [Abstract][Full Text] [Related]
7. Damoctocog Alfa Pegol: A Review in Haemophilia A.
Paik J; Deeks ED
Drugs; 2019 Jul; 79(10):1147-1156. PubMed ID: 31218660
[TBL] [Abstract][Full Text] [Related]
8. Confirmed long-term safety and efficacy of prophylactic treatment with BAY 94-9027 in severe haemophilia A: final results of the PROTECT VIII extension study.
Reding MT; Pabinger I; Holme PA; Poulsen L; Negrier C; Chalasani P; Maas Enriquez M; Wang M; Meijer K; Mancuso ME; Lalezari S
Haemophilia; 2021 May; 27(3):e347-e356. PubMed ID: 33818853
[TBL] [Abstract][Full Text] [Related]
9. Design of the HEM-POWR study: a prospective, observational study of real-world treatment with damoctocog alfa pegol in patients with haemophilia A.
Sanabria M; Álvarez Román MT; Castaman G; Janbain M; Matsushita T; Meijer K; Oldenburg J; Friedl S; Reding MT
BMJ Open; 2021 Sep; 11(9):e044997. PubMed ID: 34475142
[TBL] [Abstract][Full Text] [Related]
10. Damoctocog Alfa Pegol for Hemophilia A Prophylaxis: An Italian Multicenter Survey.
Zanon E
Pharmaceuticals (Basel); 2023 Aug; 16(9):. PubMed ID: 37765002
[TBL] [Abstract][Full Text] [Related]
11. Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A.
Solms A; Shah A; Berntorp E; Tiede A; Iorio A; Linardi C; Ahsman M; Mancuso ME; Zhivkov T; Lissitchkov T
Ann Hematol; 2020 Nov; 99(11):2689-2698. PubMed ID: 32974838
[TBL] [Abstract][Full Text] [Related]
12. A post hoc analysis of PROTECT VIII Kids assessing long-term efficacy and safety of damoctocog alfa pegol in adolescents with severe haemophilia A.
Eur J Haematol; 2024 Jun; ():. PubMed ID: 38898732
[No Abstract] [Full Text] [Related]
13. Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A.
Chowdary P; Mullins ES; Konkle BA; McGuinn C; Park YS; Stasyshyn O; Zulfikar B; Engl W; Tangada S
Haemophilia; 2020 Jul; 26(4):e168-e178. PubMed ID: 32597029
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Outcomes of Previously Treated Adult and Adolescent Patients with Severe Hemophilia A Receiving Prophylaxis with Extended Half-Life FVIII Treatments: An Economic Analysis from a United Kingdom Perspective.
Benson G; Morton T; Thomas H; Lee XY
Clinicoecon Outcomes Res; 2021; 13():39-51. PubMed ID: 33500640
[TBL] [Abstract][Full Text] [Related]
15. PROTECT VIII Kids: BAY 94-9027 (PEGylated Recombinant Factor VIII) safety and efficacy in previously treated children with severe haemophilia A.
Santagostino E; Kenet G; Fischer K; Biss T; Ahuja S; Steele M
Haemophilia; 2020 May; 26(3):e55-e65. PubMed ID: 32212300
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity profile of rurioctocog alfa pegol in previously treated patients with severe congenital hemophilia A.
Horling FM; Reipert BM; Allacher P; Engl W; Pan L; Tangada S
Blood Adv; 2024 Jun; 8(11):2726-2739. PubMed ID: 38564770
[TBL] [Abstract][Full Text] [Related]
17. Perioperative haemostasis with full-length, PEGylated, recombinant factor VIII with extended half-life (rurioctocog alfa pegol) in patients with haemophilia A: Final results of a multicentre, single-arm phase III trial.
Gruppo R; López-Fernández MF; Wynn TT; Engl W; Sharkhawy M; Tangada S
Haemophilia; 2019 Sep; 25(5):773-781. PubMed ID: 31353761
[TBL] [Abstract][Full Text] [Related]
18. Interim analyses of the multinational real-world prospective cohort HEM-POWR study evaluating the effectiveness and safety of damoctocog alfa pegol in patients with hemophilia A.
Reding MT; Álvarez-Román MT; Castaman G; Janbain M; Matsushita T; Meijer K; Schmidt K; Oldenburg J
Eur J Haematol; 2024 Feb; 112(2):286-295. PubMed ID: 37876046
[TBL] [Abstract][Full Text] [Related]
19. Real-world long-term safety and effectiveness of turoctocog alfa in the treatment of haemophilia A in Japan: results from a multicentre, non-interventional, post-marketing study.
Nagao A; Deguchi A; Nogami K
Hematology; 2024 Dec; 29(1):2316540. PubMed ID: 38376107
[TBL] [Abstract][Full Text] [Related]
20. Continued benefit demonstrated with BAY 81-8973 prophylaxis in previously treated children with severe haemophilia A: Interim analysis from the LEOPOLD Kids extension study.
Kenet G; Ljung R; Rusen L; Kerlin BA; Blanchette V; Saulytė Trakymienė S; Uscatescu V; Beckmann H; Tseneklidou-Stoeter D; Church N
Thromb Res; 2020 May; 189():96-101. PubMed ID: 32197139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
